MBX Biosciences (MBX) Cash from Operations (2023 - 2026)
MBX Biosciences (MBX) posted Cash from Operations of 20208000.0 for Q1 2026, down 10.42% sequentially from 18301000.0 in Q4 2025, and up 10.89% YoY from 18223199.62 in Q1 2025.
MBX Biosciences (MBX) Cash from Operations (2023 - 2026) Analysis & Trends
MBX Biosciences has reported Cash from Operations for 4 years, with the latest figure at 20208000.0 in Q1 2026.
- Quarterly Cash from Operations rose 10.89% year-over-year to 20208000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 77479000.0 (down 16.25% YoY) and the FY2025 annual result came in at 79949000.0, down 46.21% from the prior year.
- Cash from Operations declined to 20208000.0 in Q1 2026 per MBX's latest filing, from 18301000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 10710000.0 in Q1 2024 and troughed at 22678000.0 in Q1 2025.
- A 4-year average of 16598400.0 and a median of 16735500.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations slumped 111.75% in 2025, then rose 10.89% in 2026.
- Over 4 years, Cash from Operations stood at 11146000.0 in 2023, then plunged by 43.88% to 16037000.0 in 2024, then slipped by 14.12% to 18301000.0 in 2025, then fell by 10.42% to 20208000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 20208000.0, 18301000.0, and 21536000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | MBX Biosciences | 3.29 Bn | 3.29 Bn | - | -22.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.62 Mn |
| Jun 30, 2026 | -22.62 Mn |
| Mar 31, 2026 | -20.21 Mn |
| Mar 31, 2026 | -20.21 Mn |
| Dec 31, 2025 | -18.30 Mn |
| Dec 31, 2025 | -18.30 Mn |
| Sep 30, 2025 | -21.54 Mn |
| Sep 30, 2025 | -21.54 Mn |
| Jun 30, 2025 | -17.43 Mn |
| Jun 30, 2025 | -17.43 Mn |
| Mar 31, 2025 | -22.68 Mn |
| Mar 31, 2025 | -22.68 Mn |
| Dec 31, 2024 | -16.04 Mn |
| Dec 31, 2024 | -16.04 Mn |
| Sep 30, 2024 | -14.66 Mn |
| Sep 30, 2024 | -14.66 Mn |
| Jun 30, 2024 | -13.27 Mn |
| Jun 30, 2024 | -13.27 Mn |
| Mar 31, 2024 | -10.71 Mn |
| Mar 31, 2024 | -10.71 Mn |